section name header

Pronunciation

eye-VAB-ra-deen

Classifications

Therapeutic Classification:heart failure agents

Pharmacologic Classification: hyperpolarization-activated cyclic nucleotide-gated channel blockers

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: 40% absorbed following oral administration (undergoes first pass metabolism); food delays absorption and blood levels.

Distribution: Unknown.

Metabolism/Excretion: Extensively metabolized, primarily by the CYP3A4 enzyme system. The major metabolite is pharmacologically active and has the same potency as ivabradine. Metabolites excreted equally in urine and feces; 4% excreted unchanged in urine.

Half-life: 6 hr.

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
POunknown1 hr12 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: atrial fibrillation, bradycardia, heart block, hypertension, QT interval prolongation, sinus arrest, TORSADES DE POINTES.

EENT: phosphenes (luminous phenomena).

Interactions

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Route/Dosage

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Corlanor

Canadian Brand Names

Lancora